Insmed, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$8.9Mgeneral payments (2019-2025)
$1.1Mresearch payments (2019-2025)
16,230clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Joseph Khabbaza | Akron, OH | Pulmonary Disease | $340,850.33 |
| David Griffith | Denver, CO | Infectious Disease | $238,260.01 |
| Colin Swenson | Atlanta, GA | Pulmonary Disease | $222,764.27 |
| Wai Wong | Bethesda, MD | Ophthalmology | $175,687.50 |
| Anas Hadeh | Weston, FL | Pulmonary Disease | $165,120.13 |
| Andrew Dold | Dacula, GA | Infectious Disease | $162,680.56 |
| Juzar Ali | New Orleans, LA | Pulmonary Disease | $157,274.04 |
| Patrick Flume | Charleston, SC | Pulmonary Disease | $145,090.35 |
| Charles Daley | Denver, CO | Pulmonary Disease | $143,880.86 |
| Nicole Lapinel | New Orleans, LA | Pulmonary Disease | $140,019.97 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.